Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly -- Ignore unavailable to you. Want to Upgrade?

To: James Baker who wrote (103)	3/26/1998 12:01:00 AM
From: Wayne	Respond to of 642

Absolutely agree, James. The Evista concerns will also pass. How on Earth did the analyst revise from 3 Billion in sales to 2 Billion based on, what, a couple months of sales data? come on. Evista is a winner. And it is only one of a bunch of great drugs. LLY will be breaking new highs soon.

To: James Baker who wrote (103)	3/26/1998 2:11:00 AM
From: Sonki	Respond to of 642

Jim, i am surprised that LLY did not even go down that much even w. such revisions in salses outlook. Almost as if the street was just too caught up in dow 9k and simply overlooked. thanks for your thoughts on LLY, i still would like to find out more info...